~~<i id='9685E19C2D'><strike id='9685E19C2D'><tt id='9685E19C2D'><pre id='9685E19C2D'></pre></tt></strike></i>~~

Home» focus» Wikipedia

Wikipedia

author：hotspot 2025-10-02 08:24:31 Page View：77

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

ElaineChenofSTAT,upperleft,talkedaboutobesitydrugswith,clockwise,RaymondStevenofStructureTherapeutic

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

A rare thyroid diagnosis led to unexpected, all

Photoillustration:CaseySheneryforSTATAnnieLarsson,40,isnostrangertochronicconditions.Shewasdiagnosed